Posts by: Forest Ray PhD

Forest Ray PhD

Forest Ray received his PhD in systems biology from Columbia University, where he developed tools to match drug side effects to other diseases. He has since worked as a journalist and science writer, covering topics from rare diseases to the intersection between environmental science and social justice. He currently lives in Long Beach, California.

February 9, 2021February 9, 2021

€15M EU Project Seeks to Improve Personalized Medicine Options

News

The European Union is providing nearly €15 million ($18.1 million) over five years to improve personalized medicine options for people with drug-resistant high-grade serous ovarian cancer. The DECIDER project, funded ... Read more

October 29, 2020October 29, 2020

3 Companies Join Forces to Test Personalized ‘Teaching’ Vaccine for Ovarian Cancer

News

TransGene, NEC, and BostonGene have entered a strategic collaboration to test TG4050, an investigational personalized vaccine that aims to treat ovarian and head and neck cancers, according to a press release. TG4050 ... Read more

October 27, 2020October 27, 2020

Pilot Study Grants Available for Ovarian Cancer Research

News

Under its Pilot Study Awards program, the Rivkin Center is funding innovative research projects that seek to expand current knowledge about ovarian cancer, the non-profit has announced. Awarded grants will ... Read more

October 8, 2020October 8, 2020

Lab-Grown 3D Tumor Model Provides New Tool to Study Ovarian Cancer, Treatments

News

A lab-grown, three-dimensional (3D) ovarian tumor model will give researchers a new way to study tumor growth in ovarian cancer and to test how tumors might respond to treatments, scientists ... Read more

August 11, 2020August 11, 2020

Partnership Improves Patient Access to Apealea Outside US

News

Elevar Therapeutics and Tanner Pharma Group have partnered to make Apealea (paclitaxel micellar) accessible in areas outside the U.S. where the medication is not available. The companies have created a ... Read more

July 28, 2020July 28, 2020

Pamiparib Granted Priority Review in China for Treatment of Advanced Ovarian Cancer

News

China’s regulatory agency has granted priority review status to BeiGene‘s new drug application (NDA) requesting the approval of pamiparib, its investigational PARP inhibitor, for the treatment of advanced ovarian cancers. Priority review is ... Read more

June 30, 2020June 30, 2020

FDA’s New ‘Project Patient Voice’ to Share Symptoms Data From Cancer Trials

News, syndicated

The U.S. Food and Drug Administration (FDA) has launched an initiative called Project Patient Voice to create a publicly available information bank describing patient-reported symptoms from cancer trials for marketed ... Read more

January 28, 2020February 3, 2020

First Patient Dosed in Phase 1 Trial of SY-5609 for OC, Other Solid Tumors, Syros Announces

News

Syros Pharmaceuticals announced the dosing of the first patient in its Phase 1 trial of SY-5609, an investigational oral medication for ovarian cancer and other types of solid tumors. The ... Read more